SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SUO-CTC and CG Oncology (NASDAQ: CGON) have announced their first annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award. The fellowship aims to support outstanding clinical cancer research investigators committed to advancing NMIBC treatment and understanding. Applications are due by February 28, 2025, with the award starting in May 2025. The recipient will present their research findings at the SUO Meeting at AUA in April/May 2026.
Eligible candidates may work in basic, translational, and clinical research fields, and must have access to a research environment capable of supporting transformational NMIBC research. Applications will be evaluated based on the proposed research plan quality and available resources.
SUO-CTC e CG Oncology (NASDAQ: CGON) hanno annunciato il loro primo Premio Annuale per la Borsa di Ricerca sul Cancro della Vescica Non Muscolare Invasivo (NMIBC). La borsa ha l'obiettivo di supportare i ricercatori di oncologia clinica eccezionali impegnati nell'avanzamento del trattamento e della comprensione del NMIBC. Le candidature devono essere presentate entro il 28 febbraio 2025, con l'assegnazione che inizierà a maggio 2025. Il destinatario presenterà i risultati della sua ricerca al Meeting SUO all'AUA nell'aprile/maggio 2026.
I candidati idonei possono lavorare nei campi della ricerca di base, traslazionale e clinica, e devono avere accesso a un ambiente di ricerca in grado di supportare ricerche trasformative sul NMIBC. Le candidature saranno valutate in base alla qualità del piano di ricerca proposto e alle risorse disponibili.
SUO-CTC y CG Oncology (NASDAQ: CGON) han anunciado su primer Premio Anual de Beca de Investigación sobre el Cáncer de Vejiga No Muscularmente Invasivo (NMIBC). La beca tiene como objetivo apoyar a investigadores clínicos destacados en el campo del cáncer comprometidos con el avance del tratamiento y la comprensión del NMIBC. Las solicitudes deben presentarse antes del 28 de febrero de 2025, y la beca comenzará en mayo de 2025. El beneficiario presentará sus hallazgos de investigación en la reunión de SUO en la AUA en abril/mayo de 2026.
Los candidatos elegibles pueden trabajar en los campos de la investigación básica, traslacional y clínica, y deben tener acceso a un entorno de investigación capaz de apoyar la investigación transformacional sobre el NMIBC. Las solicitudes se evaluarán en función de la calidad del plan de investigación propuesto y de los recursos disponibles.
SUO-CTC와 CG Oncology (NASDAQ: CGON)은 첫 번째 비근육 침습성 방광암(NMIBC) 연구 펠로우십 상을 발표했습니다. 이 펠로우십은 NMIBC 치료와 이해를 발전시키기 위해 헌신하는 뛰어난 임상 암 연구자를 지원하는 것을 목표로 합니다. 지원서는 2025년 2월 28일까지 제출해야 하며, 상은 2025년 5월부터 시작됩니다. 수상자는 2026년 4월/5월 SUO 회의에서 자신의 연구 결과를 발표할 예정입니다.
지원 자격이 있는 후보자는 기초, 전이적 및 임상 연구 분야에서 일할 수 있으며, NMIBC 연구를 지원할 수 있는 연구 환경에 접근할 수 있어야 합니다. 지원서는 제안된 연구 계획의 품질과 가용 자원을 기반으로 평가됩니다.
SUO-CTC et CG Oncology (NASDAQ: CGON) ont annoncé leur premier Prix de Bourse de Recherche sur le Cancer de la Vessie Non Musculaire Invasif (NMIBC). La bourse vise à soutenir des chercheurs en oncologie clinique exceptionnels engagés dans l'avancement du traitement et de la compréhension du NMIBC. Les candidatures doivent être soumises avant le 28 février 2025, le prix débutant en mai 2025. Le lauréat présentera ses résultats de recherche lors de la réunion SUO à l'AUA en avril/mai 2026.
Les candidats éligibles peuvent travailler dans des domaines de recherche fondamentale, translationnelle et clinique, et doivent avoir accès à un environnement de recherche capable de soutenir des recherches transformationnelles sur le NMIBC. Les candidatures seront évaluées en fonction de la qualité du plan de recherche proposé et des ressources disponibles.
SUO-CTC und CG Oncology (NASDAQ: CGON) haben ihren ersten jährlichen Fellowship Award für Forschung zu nicht-muskelinvasivem Blasenkrebs (NMIBC) angekündigt. Das Fellowship zielt darauf ab, herausragende klinische Krebsforschungskräfte zu unterstützen, die sich der Verbesserung der Behandlung und des Verständnisses von NMIBC widmen. Die Bewerbungen müssen bis zum 28. Februar 2025 eingereicht werden, wobei der Preis im Mai 2025 beginnt. Der Empfänger wird seine Forschungsergebnisse auf dem SUO-Meeting der AUA im April/Mai 2026 präsentieren.
Teilnahmeberechtigte Kandidaten können in der Grundlagen-, translations- und klinischen Forschung arbeiten und müssen Zugang zu einem Forschungsumfeld haben, das transformative NMIBC-Forschung unterstützen kann. Die Bewerbungen werden basierend auf der Qualität des vorgeschlagenen Forschungsplans und den verfügbaren Ressourcen bewertet.
- None.
- None.
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC
SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the first annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
“There remains a significant unmet need for treating NMIBC, and this fellowship will help advance research and drive innovation, leading to improvements in patient care,” said Sia Daneshmand, MD, Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center and Chair of the Bladder Cancer Committee of the SUO-CTC.
Colin Dinney, MD, Chairman, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, continued, “We are fortunate to have a very bright and motivated next generation of urologists coming into the field, and this is a great opportunity for them to collaborate with their mentors and present it at a prominent forum like AUA in 2026.”
“CG Oncology is honored to partner with the SUO-CTC on this important fellowship,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “We share a commitment to ultimately deliver better quality of life to patients with urologic cancers. This fellowship is another important step that will advance research and ultimately help patients.”
To apply for this fellowship, investigators may be working in basic, translational and clinical research fields, and they must be working in a research environment capable of supporting transformational NMIBC research. All applications are due by Friday, February 28, 2025, at 5:00 PM U.S. Eastern Time. Applications will be evaluated on the quality of the applicant’s proposed research plan and the resources and environment available to the applicant.
The award start date will be in May 2025 and the Award recipient will present their research results at the conclusion of the Award at SUO Meeting at the AUA in April/May 2026.
To learn more and to view the application, please visit https://suoctc.org/
About Bladder Cancer
More than 83,000 people are estimated to be diagnosed with bladder cancer in 2024. NMIBC is the most common form of bladder cancer, representing approximately
About The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC)
SUO-CTC is a clinical research investigator network of over 600 members from more than 300 clinical sites in the U.S. and Canada. This national alliance of leading academic and community based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and has a cooperative relationship with the Society of Urologic Oncology (SUO). To learn more please visit: https://suoctc.org/
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts:
SUO-CTC
Pam Murphy
Executive Director, Clinical Research Services
(847) 264-5978
pam@wjweiser.com
CG Oncology
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Chau Cheng
Vice President, Investor Relations, CG Oncology
(949) 342-8939
chau.cheng@cgoncology.com
FAQ
When is the application deadline for the CG Oncology (CGON) NMIBC Research Fellowship?
What is the duration of the CG Oncology (CGON) NMIBC Research Fellowship?
Who is eligible for the CG Oncology (CGON) NMIBC Research Fellowship?
Where will the CG Oncology (CGON) NMIBC Research Fellowship results be presented?
